In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment

Bone

Volumn 27, Issue 2, 2000, Pages 209-218

  Stanislaus, D ^a   Yang, X ^a   Liang, J D ^a   Wolfe, J ^b   Cain, R L ^a   Onyia, J E ^a,b   Falla, N ^a   Marder, P ^a   Bidwell, J P ^b   Queener, S W ^a   Hock, J M ^a,b  

^a ELI LILLY AND COMPANY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF DENTISTRY   (United States)

Author keywords

Apoptosis; Caspase enzymes; Osteoblasts; Osteocytes; Parathyroid hormone (PTH); Rats

Indexed keywords

GROWTH FACTOR RECEPTOR; LIPOCORTIN 5; MESSENGER RNA; PARATHYROID HORMONE RECEPTOR; PARATHYROID HORMONE[1-34]; RECOMBINANT HORMONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; MALE; METAPHYSIS; NICK END LABELING; NONHUMAN; OSTEOBLAST; PROTEIN EXPRESSION; RAT; TRABECULAR BONE;

EID: 18144452145     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(00)00309-4     Document Type: Article

References (30)

1. Delmas P.D., Vergnaud P., Arlot M.E., Pastoureau P., Meunier P.J., Nilssen M.H. The anabolic effect of human PTH(1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate - Is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone. 16:1995;603-610.
2. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 136:1995;3632-3638.
3. Frisch S.M., Ruoslahti E. Integrins and anoikis. Curr Opin Cell Biol. 9:1997;701-706.
4. Frolik C.A., Cain R.L., Sato M., Harvey A.K., Chandrasekhar S., Black E.C., Tashjian A.H. Jr, Hock J.M. Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271) In vitro activity and in vivo pharmacological effects in rats . J Bone Miner Res. 14:1999;163-172. [see comments].
5. Garcia Calvo M., Peterson E.P., Rasper D.M., Vaillancourt J.P., Zamboni R., Nicholson D.W., Thornberry N.A. Purification and catalytic properties of human caspase family members. Cell Death Differ. 6:1999;362-369.
6. Gunness-Hey M., Hock J.M. Increased trabecular bone mass in rats treated with human synthetic parathyroid hormone. Metab Bone Dis Rel Res. 5:1984;177-181.
7. Gunness-Hey M., Hock J.M. Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone. 10:1989;447-452.
8. Hock J., Onyia J., Miller B., Hulman J., Herring J., Chandrasekhar S., Harvey A., Gunness M. Anabolic PTH targets proliferating cells of the primary spongiosa in young rats and increases the number that differentiate into osteoblasts. J Bone Miner Res. 9:(Suppl.):1994;S412.
9. Hock J.M., Gera I., Fonseca J., Raisz L.G. Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. Endocrinology. 122:1988;2899-2904.
10. Hock J.M., Hummert J.R., Boyce R., Fonseca J., Raisz L.G. Resorption is not essential for the stimulation of bone growth by hPTH-(1-34) in rats in vivo. J Bone Miner Res. 4:1989;449-458.
11. Hodsman A.B., Steer B.M. Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis Evidence for de novo bone formation on quiescent cancellous surfaces . Bone. 14:1993;523-527.
12. Hodsman A.B., Steer B.M., Fraher L.J., Drost D.J. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner. 14:1991;67-83.
13. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 104:1999;439-446.
14. Kimmel D.B., Jee W.S. Bone cell kinetics during longitudinal bone growth in the rat. Calcif Tissue Int. 32:1980;123-133.
15. Kotowicz M.A., Klee G.G., Kao P.C., O'Fallon W.M., Hodgson S.F., Cedel S.L., Eriksen E.F., Gonchoroff D.G., Judd H.L., Riggs B.L. Relationship between serum intact parathyroid hormone concentrations and bone remodeling in type I osteoporosis Evidence that skeletal sensitivity is increased . Osteopor Int. 1:1990;14-22.
16. Leaffer D., Sweeney M., Kellerman L.A., Avnur Z., Krstenansky J.L., Vickery B.H., Caulfield J.P. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). Endocrinology. 136:1995;3624-3631.
17. Lynch M.P., Capparelli C., Stein J.L., Stein G.S., Lian J.B. Apoptosis during bone-like tissue development in vitro. J Cell Biochem. 68:1998;31-49.
18. Margolis R.N., Canalis E., Partridge N.C. Invited review of a workshop Anabolic hormones in bone: Basic research and therapeutic potential . J Clin Endocrinol Metab. 81:1996;872-877.
19. McClelland P., Onyia J.E., Miles R.R., Tu Y., Liang J., Harvey A.K., Chandrasekhar S., Hock J.M., Bidwell J.P. Intermittent administration of parathyroid hormone (1-34) stimulates matrix metalloproteinase-9 (MMP-9) expression in rat long bone. J Cell Biochem. 70:1998;391-401.
20. Mosekilde L., Sogaard C.H., Danielsen C.C., Torring O. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing A comparison study between hPTH-(1-34) and hPTH-(1-84) . Endocrinology. 129:1991;421-428.
21. Nicholson D.W., Thornberry N.A. Caspases Killer proteases . Trends Biochem Sci. 22:1997;299-306.
22. Onyia J.E., Miller B., Hulman J., Liang J., Galvin R., Frolik C., Chandrasekhar S., Harvey A.K., Bidwell J., Herring J., Hock J.M. Proliferating cells in the primary spongiosa express osteoblastic phenotype in vitro. Bone. 20:1997;93-100.
23. Parfitt A.M. The actions of parathyroid hormone on bone Relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part III. PTH and osteoblasts, the relationship between bone turnover and bone loss, and the state of the bones in primary hyperparathyroidism . Metabol Clin Exp. 25:1976;1033-1069.
24. Peeters-Joris C., Hammani K., Singer C.F. Differential regulation of MMP-13 (collagenase-3) and MMP-3 (stromelysin-1) in mouse calvariae. Biochim Biophys Acta. 1405:1998;14-28.
25. Pfeilschifter J., Oechsner M., Naumann A., Gronwald R.G., Minne H.W., Ziegler R. Stimulation of bone matrix apposition in vitro by local growth factors A comparison between insulin-like growth factor I, platelet-derived growth factor, and transforming growth factor beta . Endocrinology. 127:1990;69-75.
26. Salvesen G.S. Programmed cell death and the caspases. Acta Pathol Microbiol, Immunol Scand. 107:1999;73-79.
27. Sato M., Zeng G.Q., Turner C.H. Biosynthetic human parathyroid hormone (1-34) effects on bone quality in aged ovariectomized rats. Endocrinology. 138:1997;4330-4337.
28. Thompson C.B. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
29. Weinstein R.S., Chambers T.M., Crawford J.A., Swain F.A., Parfitt A.M., Jilka R.L., Manolagas S.C. A strong positive correlation between the prevalence of osteoblast apoptosis and the activation frequency across a wide range of bone remodeling rates. J Bone Miner Res. 14:(Suppl. 1):1999;S342.
30. Wronski T.J., Yen C.F., Qi H., Dann L.M. Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology. 132:1993;823-831.